Tidal Investments LLC Acquires 2,319 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Tidal Investments LLC raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 37.8% in the third quarter, Holdings Channel reports. The fund owned 8,452 shares of the medical research company’s stock after buying an additional 2,319 shares during the quarter. Tidal Investments LLC’s holdings in Charles River Laboratories International were worth $1,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International during the third quarter worth about $32,000. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $59,000. 98.91% of the stock is currently owned by institutional investors.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of analyst reports. UBS Group upped their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, September 20th. Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Finally, Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $214.00.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $189.39 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The firm’s 50 day moving average is $194.42 and its 200-day moving average is $202.68. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 23.70, a PEG ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the business earned $2.72 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).